Prophylactic Administration of Calf Lung Surfactant Extract Is More Effective Than Early Treatment of Respiratory Distress Syndrome in Neonates of 29 Through 32 Weeks' Gestation

¹ From the University of Virginia, Charlottesville
² From the HCA Wesley Medical Center, Wichita, KS
³ From the Prentice Women's Hospital, Chicago, IL
⁴ From the Evanston Hospital, Evanston, IL
⁵ Temple University School of Medicine, Philadelphia, PA
⁶ From the University of Utah School of Medicine, Salt Lake City
⁷ From the Schneider Children's Hospital, New Hyde Park, NY
⁸ From the Medical College of Virginia, Richmond

Objective. Although numerous trials have demonstrated the efficacy of exogenous surfactant for prophylaxis or treatment of neonatal respiratory distress syndrome (RDS), optimum timing of administration remains controversial. One previous study showed that administration of calf lung surfactant extract immediately following birth, to neonates born before 30 weeks postconceptional age, was preferable to delaying administration until after development of RDS. The current study was designed to test a similar hypothesis for babies born between 29 and 32 weeks gestational age.

Design. One thousand three hundred ninety-eight neonates with obstetric estimates of 29 through 32 weeks' gestation were randomized to receive CLSE at birth or to wait until development of mild RDS. After exclusions for malformations and other factors, data from 1248 were analyzed.

Results. Prophylaxis was associated with less development of moderate RDS (7% vs 12%), less need for retreatment (5% vs 9%), less need for mechanical ventilation or supplemental oxygen during the first 4 days, and fewer deaths or less requirement for supplemental oxygen at 28 days (5% vs 9%). Although 1-minute Apgar scores were significantly lower in the prophylaxis group, the difference disappeared by the 5-minute score and there was no difference in the incidence of asphyxiarelated complications. Sixty percent of the neonates assigned to early treatment received endotracheal intubation and 43% received calf lung surfactant extract at a median age of 1.5 hours. When data were analyzed by gestational age and birth weight subgroups, most of the differences could be attributable to babies born at 30 weeks or less or weighing less than 1500 g, probably because of the higher incidence of surfactant deficiency in this more immature subgroup.

Key Words: neonate • surfactant • respiratory distress syndrome

Submitted on September 8, 1992
Accepted on February 1, 1993

This article has been cited by other articles:

				W. A. Engle and and the Committee on Fetus and Newborn Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate Pediatrics, February 1, 2008; 121(2): 419 - 432. [Abstract] [Full Text] [PDF]

				M. Ghodrat Lung surfactants. Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521. [Abstract] [Full Text] [PDF]

				G. A. Agrons, S. E. Courtney, J. T. Stocker, and R. I. Markowitz From the Archives of the AFIP: Lung Disease in Premature Neonates: Radiologic-Pathologic Correlation RadioGraphics, July 1, 2005; 25(4): 1047 - 1073. [Abstract] [Full Text] [PDF]

				P. D Reiter, C. Sims, L. Harmes, J. Paisley, A. A Rosenberg, and R. J Valuck Calfactant Sterility in Multiple Doses from Single-Use Vials Ann. Pharmacother., September 1, 2003; 37(9): 1219 - 1223. [Abstract] [Full Text] [PDF]

				D. A. Osborn, H. E. Jeffery, S. L. Bredemeyer, J. M. Polverino, and S. Reid Targeted Early Rescue Surfactant in Ventilated Preterm Infants Using the Click Test Pediatrics, September 1, 2000; 106(3): 30e - 30. [Abstract] [Full Text]

				J. Kattwinkel, B. T. Bloom, P. Delmore, C. Glick, D. Brown, S. Lopez, L. Willett, E. A. Egan, M. Conaway, and J. Patrie High-Versus Low-Threshold Surfactant Retreatment For Neonatal Respiratory Distress Syndrome Pediatrics, August 1, 2000; 106(2): 282 - 288. [Abstract] [Full Text]

				Committee on Fetus and Newborn Surfactant Replacement Therapy for Respiratory Distress Syndrome Pediatrics, March 1, 1999; 103(3): 684 - 685. [Abstract] [Full Text]

				L. Gortner, R. R. Wauer, H. Hammer, G.-J. Stock, F. Heitmann, H. L. Reiter, P. G. Kühl, J. C. Möller, H.-J. Friedrich, I. Reiss, et al. Early Versus Late Surfactant Treatment in Preterm Infants of 27 to 32 Weeks' Gestational Age: A Multicenter Controlled Clinical Trial Pediatrics, November 1, 1998; 102(5): 1153 - 1160. [Abstract] [Full Text]

				J. TYEBKHAN and P. C ETCHES Prophylactic vs rescue surfactant and antenatal corticosteroids Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1998; 79(1): 79F - 79. [Full Text]

				J. W. Kendig, R. M. Ryan, R. A. Sinkin, W. M. Maniscalco, R. H. Notter, R. Guillet, C. Cox, H. S. Dweck, M. J. Horgan, L. J. Reubens, et al. Comparison of Two Strategies for Surfactant Prophylaxis in Very Premature Infants: A Multicenter Randomized Trial Pediatrics, June 1, 1998; 101(6): 1006 - 1012. [Abstract] [Full Text] [PDF]

				R. A. Sinkin, B. M. Kramer, J. L. Merzbach, G. J. Myers, J. G. Brooks, D. R. Palumbo, C. Cox, J. W. Kendig, C. E. Mercier, and D. L. Phelps School-age Follow-up of Prophylactic Versus Rescue Surfactant Trial: Pulmonary, Neurodevelopmental, and Educational Outcomes Pediatrics, May 1, 1998; 101 (5): e11 - e11. [Abstract] [Full Text] [PDF]

				B. T. Bloom, J. Kattwinkel, R. T. Hall, P. M. Delmore, E. A. Egan, J. R. Trout, M. H. Malloy, D. R. Brown, I. R. Holzman, C. H. Coghill, et al. Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome Pediatrics, July 1, 1997; 100(1): 31 - 38. [Abstract] [Full Text] [PDF]

				M. L. Hudak, D. J. Martin, E. A. Egan, E. J. Matteson, J. Cummings, A. L. Jung, L. V. Kimberlin, R. L. Auten, A. A. Rosenberg, J. M. Asselin, et al. A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome Pediatrics, July 1, 1997; 100(1): 39 - 50. [Abstract] [Full Text] [PDF]

				J. Egberts, R. Brand, H. Walti, G. Bevilacqua, G. B. MD, and F. Gardini Mortality, Severe Respiratory Distress Syndrome, and Chronic Lung Disease of the Newborn Are Reduced More After Prophylactic Than After Therapeutic Administration of the Surfactant Curosurf Pediatrics, July 1, 1997; 100(1): e4 - e4. [Abstract] [Full Text] [PDF]

				C J Morley Systematic review of prophylactic vs rescue surfactant Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1997; 77(1): 70F - 74. [Full Text]